Therese Lindberg

therese.lindberg@cambio.se

Cambio CDS

Cryoprecipitate is an important, but seldom used, blood component and providers seeking to administer this product may not be aware of appropriate dosing strategies. This calculation should promote accurate and evidence-based dosing of this blood product.

Use on patients with isolated or exaggerated acquired decreases in fibrinogen (hypofibrinogenemia or hyperfibrinolysis) requiring transfusion with cryoprecipitate (also referred to as cryo and cryoprecipitated antihemophilic factor). Dose, units = desired fibrinogen increment, mg/dL × plasma volume, dL / 250 mg/unit Where desired fibrinogen increment = goal fibrinogen – initial fibrinogen and plasma volume = (1 – hematocrit) × 70 mL/kg × weight, kg Note: the equation used here assumes a typical fibrinogen content of 250 mg per unit of cryo. As a biological product, fibrinogen content can vary somewhat from unit-to-unit, but should contain at least 150 mg / unit.

This dosing tool is intended to assist with calculation, not to provide comprehensive or definitive drug information. Always double-check dosing of any drug and consult a pharmacist when necessary. Do not use to dose other factors found in cryo (e.g. Factor XIII, Factor VIII, von Willebrand Factor) or to dose fibrinogen concentrate.

1. Roback JD. Technical Manual. American Association of Blood Banks (AABB); 2014.

OBSERVATION.cryoprecipitate_dosing_fibrinogen_replacement.v0, OBSERVATION.lab_test_fibrinogen.v0